Ovid Therapeutics Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ovid Therapeutics Inc. on December 6, 2023, covering an event that occurred on December 4, 2023. The filing pertains to a specific corporate event under Item 8.01 (Other Events) and does not contain a comprehensive financial report for a fiscal period.
Key Financial Metrics
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a change in beneficial ownership by a company executive.
Material Changes
The material change reported is a transfer of equity ownership:
- Event: Jeremy Levin, DPhil, MB BChir, the Company's Chief Executive Officer and Chairman, gifted shares of common stock to family trusts for the benefit of his two daughters as part of year-end estate tax planning.
- Shares Transferred: 1,146,500 shares.
- Consideration: The transfers were made for no consideration.
- Post-Transaction Holdings: Following the gift, Dr. Levin holds 3,598,467 shares of the Company's outstanding common stock.
- Regulatory Filing: Dr. Levin filed a Form 4 with the SEC on December 6, 2023, to report this change in ownership.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items beyond the specific ownership transfer described above.
Investor Verification Points
- Verify the Form 4 filed by Jeremy Levin on December 6, 2023, to confirm the exact number of shares transferred and his remaining beneficial ownership.
- Review the Company's most recent 10-K or 10-Q filings for current financial performance, cash position, and liquidity metrics, as this 8-K does not contain such data.
- Confirm the total number of outstanding shares of common stock to assess the percentage of ownership represented by Dr. Levin's remaining holdings.